Shares of Bajaj Healthcare zoomed 20 per cent and hit a new high of Rs 863.95 on the BSE in intra-day deal on Tuesday after the company announced that it has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug “Baricitinib” (API and formulation). Bajaj Healthcare is a leading manufacturer of active pharmaceutical ingredients (APIs), intermediates, and formulations.